An observational study in Juvenile Idiopathic Arthritis, Familial Mediterranean Fever and Healty Controls, sponsored by Istanbul University - Cerrahpasa. Completed at 1 site in Turkey. Open to participants aged 12 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-05.
Sponsored by Istanbul University - Cerrahpasa · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Arthritis, Juvenile by Istanbul University - Cerrahpasa — 6 open to participants now, 6 under way, none of them phase 3. Arthritis, Juvenile · Istanbul University - Cerrahpasa.
Among the 13 studies in Arthritis, Juvenile by Istanbul University - Cerrahpasa, this one is one of 6 that started in 2024, is one of 5 observational ones, and was the 8th registered.
365 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.
Browse Arthritis, Juvenile studies →6 of the 13 studies in Arthritis, Juvenile by Istanbul University - Cerrahpasa are open now, in 1 country. Recruiting first, the newest first:
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 8–12
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 8–16 · Healthy volunteers
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 13–18 · Healthy volunteers
Istanbul University - Cerrahpasa
Ages 10–18
Istanbul University - Cerrahpasa
Ages 6–18 · Healthy volunteers
By country, each count listing its studies:
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 12 Years to 18 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 6 started in 2024.
This study's enrollment of 216 is above the median of 120 across 118 observational studies indexed under Arthritis, Juvenile.
Median enrollment 35 across the 8 interventional studies, 70 across the 5 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Istanbul University - Cerrahpasa is the lead sponsor of 701 studies on the registry; 211 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Arthritis, Juvenile by Istanbul University - Cerrahpasa, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Juvenile Idiopathic Arthritis (JIA) and Familial Mediterranean Fever (FMF) are the most common autoimmune and autoinflammatory rheumatic diseases in childhood. Symptoms such as reduced muscle strength, joint pain, fatigue, and limited activity, which are common in childhood rheumatic diseases, often lead to impaired physical function. Cardiorespiratory fitness, which is an important indicator of physical function, plays a critical role in health-related outcomes in children and adolescents with rheumatic disease. Maximum oxygen consumption (VO2 peak) is considered the fundamental criterion for evaluating cardiorespiratory fitness. The need for extensive equipment and trained personnel, accompanied with the inability to assess large numbers of children at one-time makes the objective assessment of cardiorespiratory fitness in a clinic setting unmanageable. Therefore, there is a need to assess their cardiorespiratory fitness utilizing an easily administered test that has minimal measurement errors in patients with JIA and FMF. The Progressive Aerobic Cardiovascular Endurance Run (PACER) has become a routine cardiorespiratory fitness assessment for predicting VO2peak in children. A review of the literature revealed that no studies have evaluated CRF using PACER in childhood rheumatic diseases. The aim of this study was to compare the Fitnessgram VO2 max values of children and adolescents diagnosed with JIA and FMF with those of their healthy peers and to examine the relationship with body composition.
Patients diagnosed with JIA and FMF, and their healthy peers without any chronic diseases or disabilities, all aged between 12 to 18 years old will be evaluated with PACER.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients diagnosed with JIA followed at the Pediatric Rheumatology Clinic, Department of Pediatrics, Istanbul Faculty of Medicine, will be evaluated.
Other: Usability and Comparison
Patients diagnosed with FMF followed at the Pediatric Rheumatology Clinic, Department of Pediatrics, Istanbul Faculty of Medicine, will be evaluated.
Other: Usability and Comparison
The outcomes of individuals with rheumatic diseases will be compared with those of healthy controls.
Other: Usability and Comparison
PACER will be used to assess cardiorespiratory fitness in individuals with rheumatic diseases. The results will be compared with those of healthy individuals, and the relationship between body composition and VO2 max will be examined.
Progressive Aerobic Cardiovascular Endurance Run (PACER)
The PACER test is an adapted version of the 20-meter shuttle run test and consists of multiple stages, serving as a field test. It allows children and adolescents to set their own pace and warm up, serving as a more enjoyable alternative to other distance running tests recommended for use in children, adolescents, and young adults. Utilized to assess patients' cardiorespiratory fitness, individuals were instructed to run back and forth between two cones within a 20-meter course, to the rhythm of music played through a sound recording device, with the test starting at a slow pace and gradually increasing in speed every minute.
Time frame: Baseline
Body Mass Index
Body mass index (BMI), will determined by dividing the body weight in kilograms by the square of the height in meters.
Time frame: Baseline
VO2 max
Using the FitnessGram software, the maximum oxygen consumption value (VO2max) will calculated for each individual based on the number of laps completed.
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2024 to primary completion in Jan 2025, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istanbul University - Cerrahpasa →